{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:24:19Z","timestamp":1790036659976,"version":"4.0.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005275","name":"Region Hovedstaden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005275","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001734","name":"Copenhagen University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001734","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Platelet-rich plasma (PRP) as a regenerative therapy has gained interest in the field of andrology for the treatment of erectile dysfunction (ED) and Peyronie\u2019s disease (PD). This systematic review aims to critically evaluate the current evidence on the use of PRP for these conditions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We performed a systematic literature search according to the PRISMA guidelines using PubMed and Scopus databases in December 2023. Studies were included if they evaluated the effect of PRP therapy for ED or PD in humans.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We identified 164 articles, 17 of which were included, consisting of 11 studies on ED, 5 studies on PD, and 1 study on both. We included four randomized controlled trials, 11 prospective cohort studies, and three retrospective cohort studies including a total of 1099 patients. The studies on ED and PD generally showed small to moderate benefits with mild and transient side effects and no major adverse events were reported. General limitations included variations in PRP protocols, small sample sizes, short follow-up periods, and lack of control groups except in the three randomized trials on ED and the one on PD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The literature on PRP therapy in andrology is limited and difficult to interpret due to variations in protocols and methodological drawbacks. Further research is necessary to determine the optimal preparation and treatment protocols for PRP therapy and clarify its effectiveness in andrology.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00345-024-05065-3","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T17:02:01Z","timestamp":1717002121000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Platelet-rich plasma therapy in erectile dysfunction and Peyronie\u2019s disease: a systematic review of the literature"],"prefix":"10.1007","volume":"42","author":[{"given":"Maria Giovanna","family":"Asmundo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil","family":"Durukan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"von Rohden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra Amalie","family":"Thy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian Fuglesang Skj\u00f8dt","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8963-4581","authenticated-orcid":false,"given":"Mikkel","family":"Fode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,29]]},"reference":[{"key":"5065_CR1","doi-asserted-by":"publisher","first-page":"7794","DOI":"10.3390\/ijms21207794","volume":"21","author":"P Everts","year":"2020","unstructured":"Everts P, Onishi K, Jayaram P, Lana JF, Mautner K (2020) Platelet-rich plasma: new performance understandings and therapeutic considerations in 2020. Int J Mol Sci 21:7794. https:\/\/doi.org\/10.3390\/ijms21207794","journal-title":"Int J Mol Sci"},{"key":"5065_CR2","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1159\/000477353","volume":"4","author":"R Alves","year":"2018","unstructured":"Alves R, Grimalt R (2018) A review of platelet-rich plasma: history, biology, mechanism of action, and classification. Skin Appendage Disord 4:18\u201324. https:\/\/doi.org\/10.1159\/000477353","journal-title":"Skin Appendage Disord"},{"key":"5065_CR3","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1177\/0363546517746112","volume":"47","author":"BW Oudelaar","year":"2019","unstructured":"Oudelaar BW, Peerbooms JC, Huisin\u2019t Veld R, Vochteloo AJH (2019) Concentrations of blood components in commercial platelet-rich plasma separation systems: a review of the literature. Am J Sports Med 47:479\u2013487. https:\/\/doi.org\/10.1177\/0363546517746112","journal-title":"Am J Sports Med"},{"key":"5065_CR4","doi-asserted-by":"publisher","first-page":"645","DOI":"10.2217\/rme.13.59","volume":"8","author":"I Andia","year":"2013","unstructured":"Andia I, Abate M (2013) Platelet-rich plasma: underlying biology and clinical correlates. Regener Med 8:645\u2013658. https:\/\/doi.org\/10.2217\/rme.13.59","journal-title":"Regener Med"},{"key":"5065_CR5","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1001\/archfacial.2011.784","volume":"14","author":"SA McCormick","year":"2012","unstructured":"McCormick SA (2012) Induction of dermal collagenesis, angiogenesis, and adipogenesis in human skin by injection of platelet-rich fibrin matrix. Arch Facial Plast Surg 14:132. https:\/\/doi.org\/10.1001\/archfacial.2011.784","journal-title":"Arch Facial Plast Surg"},{"key":"5065_CR6","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.sxmr.2018.12.006","volume":"7","author":"S Scott","year":"2019","unstructured":"Scott S, Roberts M, Chung E (2019) Platelet-rich plasma and treatment of erectile dysfunction: critical review of literature and global trends in platelet-rich plasma clinics. Sex Med Rev 7:306\u2013312. https:\/\/doi.org\/10.1016\/j.sxmr.2018.12.006","journal-title":"Sex Med Rev"},{"key":"5065_CR7","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/aja.2008.37","volume":"11","author":"X-G Ding","year":"2009","unstructured":"Ding X-G, Li S-W, Zheng X-M, Hu L-Q, Hu W-L, Luo Y (2009) The effect of platelet-rich plasma on cavernous nerve regeneration in a rat model. Asian J Androl 11:215\u2013221. https:\/\/doi.org\/10.1038\/aja.2008.37","journal-title":"Asian J Androl"},{"key":"5065_CR8","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1111\/j.1743-6109.2012.02881.x","volume":"9","author":"C Wu","year":"2012","unstructured":"Wu C, Wu Y, Ho H, Chen K, Sheu M, Chiang H (2012) The neuroprotective effect of platelet-rich plasma on erectile function in bilateral cavernous nerve injury rat model. J Sex Med 9:2838\u20132848. https:\/\/doi.org\/10.1111\/j.1743-6109.2012.02881.x","journal-title":"J Sex Med"},{"key":"5065_CR9","unstructured":"Salonia A MSBCCPCGHG (2023) EAU guidelines on sexual and reproductive health 2023 https:\/\/uroweb.org\/guidelines\/sexual-and-reproductive-health\/chapter\/citation-information (accessed 24 Apr 2023)"},{"key":"5065_CR10","doi-asserted-by":"publisher","first-page":"W65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","volume":"151","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JPA et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 151:W65-94. https:\/\/doi.org\/10.7326\/0003-4819-151-4-200908180-00136","journal-title":"Ann Intern Med"},{"key":"5065_CR11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1472-6947-7-16","volume":"7","author":"C Schardt","year":"2007","unstructured":"Schardt C, Adams MB, Owens T, Keitz S, Fontelo P (2007) Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Med Inform Decis Mak 7:16. https:\/\/doi.org\/10.1186\/1472-6947-7-16","journal-title":"BMC Med Inform Decis Mak"},{"key":"5065_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD et al (2011) The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928. https:\/\/doi.org\/10.1136\/bmj.d5928","journal-title":"BMJ"},{"key":"5065_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"5065_CR14","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/S0090-4295(97)00238-0","volume":"49","author":"RC Rosen","year":"1997","unstructured":"Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A (1997) The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 49:822\u2013830. https:\/\/doi.org\/10.1016\/S0090-4295(97)00238-0","journal-title":"Urology"},{"key":"5065_CR15","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/sj.ijir.3900472","volume":"11","author":"R Rosen","year":"1999","unstructured":"Rosen R, Cappelleri J, Smith M, Lipsky J, Pe\u00f1a B (1999) Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 11:319\u2013326. https:\/\/doi.org\/10.1038\/sj.ijir.3900472","journal-title":"Int J Impot Res"},{"key":"5065_CR16","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.urology.2023.01.028","volume":"175","author":"H Shaher","year":"2023","unstructured":"Shaher H, Fathi A, Elbashir S, Abdelbaki SA, Soliman T (2023) Is platelet rich plasma safe and effective in treatment of erectile dysfunction? Random Control Study Urol 175:114\u2013119. https:\/\/doi.org\/10.1016\/j.urology.2023.01.028","journal-title":"Random Control Study Urol"},{"key":"5065_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/and.14162","author":"AS Zaghloul","year":"2021","unstructured":"Zaghloul AS, Mahmoud ElNashar AER, GamalEl Din SF, Zaki Said S, Saad HM, Refaat Eldebs H et al (2021) Smoking status and the baseline international index of erectile function score can predict satisfactory response to platelet-rich plasma in patients with erectile dysfunction: a prospective pilot study. Andrologia. https:\/\/doi.org\/10.1111\/and.14162","journal-title":"Andrologia"},{"key":"5065_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/and.14421","author":"AS Zaghloul","year":"2022","unstructured":"Zaghloul AS, El-Nashaar AM, Said SZ, Osman IA, Mostafa T (2022) Assessment of the intracavernosal injection platelet-rich plasma in addition to daily oral tadalafil intake in diabetic patients with erectile dysfunction non-responding to on-demand oral PDE5 inhibitors. Andrologia. https:\/\/doi.org\/10.1111\/and.14421","journal-title":"Andrologia"},{"key":"5065_CR19","doi-asserted-by":"publisher","first-page":"100313","DOI":"10.1016\/j.esxm.2020.100313","volume":"9","author":"T Ta\u015f","year":"2021","unstructured":"Ta\u015f T, \u00c7ak\u0131ro\u011flu B, Arda E, Onuk \u00d6, Nuho\u011flu B (2021) Early clinical results of the tolerability, safety, and efficacy of autologous platelet-rich plasma administration in erectile dysfunction. Sex Med 9:100313\u2013100313. https:\/\/doi.org\/10.1016\/j.esxm.2020.100313","journal-title":"Sex Med"},{"key":"5065_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.4111\/icu.2018.59.1.61","volume":"59","author":"EL Matz","year":"2018","unstructured":"Matz EL, Pearlman AM, Terlecki RP (2018) Safety and feasibility of platelet rich fibrin matrix injections for treatment of common urologic conditions. Investig Clin Urol 59:61. https:\/\/doi.org\/10.4111\/icu.2018.59.1.61","journal-title":"Investig Clin Urol"},{"key":"5065_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/and.14197","author":"S Geyik","year":"2021","unstructured":"Geyik S (2021) Comparison of the efficacy of low-intensity shock wave therapy and its combination with platelet-rich plasma in patients with erectile dysfunction. Andrologia. https:\/\/doi.org\/10.1111\/and.14197","journal-title":"Andrologia"},{"key":"5065_CR22","doi-asserted-by":"publisher","first-page":"171","DOI":"10.4103\/UROS.UROS_22_21","volume":"32","author":"S-M Wong","year":"2021","unstructured":"Wong S-M, Chiang B-J, Chen H-C, Wu Y-N, Lin Y-H, Liao C-H (2021) A short term follow up for intracavernosal injection of platelet rich plasma for the treatment of erectile dysfunction. Urol Sci 32:171. https:\/\/doi.org\/10.4103\/UROS.UROS_22_21","journal-title":"Urol Sci"},{"key":"5065_CR23","doi-asserted-by":"publisher","first-page":"168","DOI":"10.9734\/jpri\/2021\/v33i32A31730","volume":"2021","author":"K Sajjad","year":"2021","unstructured":"Sajjad K, Sohail M, Momin HA, Shafique RA, Nazir M, Ahmad S et al (2021) Effect of low-energy shockwave therapy versus platelets rich plasma therapy in patients with erectile dysfunction. J Pharm Res Int 2021:168\u2013172. https:\/\/doi.org\/10.9734\/jpri\/2021\/v33i32A31730","journal-title":"J Pharm Res Int"},{"key":"5065_CR24","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.purol.2022.05.002","volume":"32","author":"A Schirmann","year":"2022","unstructured":"Schirmann A, Boutin E, Faix A, Yiou R (2022) Pilot study of intra-cavernous injections of platelet-rich plasma (P-shot\u00ae) in the treatment of vascular erectile dysfunction. Prog Urol 32:1440\u20131445. https:\/\/doi.org\/10.1016\/j.purol.2022.05.002","journal-title":"Prog Urol"},{"key":"5065_CR25","doi-asserted-by":"publisher","DOI":"10.23736\/S2724-6507.23.04060-5","author":"D Francomano","year":"2023","unstructured":"Francomano D, Iuliano S, Deh\u00f2 F, Capogrosso P, Tuzzolo P, La Vignera S et al (2023) Regenerative treatment with platelet-rich plasma in patients with refractory erectile dysfunction: short-term outcomes and predictive value of mean platelet volume. Minerva Endocrinol. https:\/\/doi.org\/10.23736\/S2724-6507.23.04060-5","journal-title":"Minerva Endocrinol"},{"key":"5065_CR26","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.jsxm.2021.03.008","volume":"18","author":"E Poulios","year":"2021","unstructured":"Poulios E, Mykoniatis I, Pyrgidis N, Zilotis F, Kapoteli P, Kotsiris D et al (2021) Platelet-rich plasma (PRP) improves erectile function: a double-blind, randomized placebo-controlled clinical. Trial J Sex Med 18:926\u2013935. https:\/\/doi.org\/10.1016\/j.jsxm.2021.03.008","journal-title":"Trial J Sex Med"},{"key":"5065_CR27","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/JU.0000000000003481","volume":"210","author":"TA Masterson","year":"2023","unstructured":"Masterson TA, Molina M, Ledesma B, Zucker I, Saltzman R, Ibrahim E et al (2023) Platelet-rich plasma for the treatment of erectile dysfunction: a prospective, randomized, double-blind placebo-controlled clinical Trial. J Urol 210:154\u2013161. https:\/\/doi.org\/10.1097\/JU.0000000000003481","journal-title":"J Urol"},{"key":"5065_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41443-023-00744-y","author":"AS Zugail","year":"2023","unstructured":"Zugail AS, Alshuaibi M, Lombion S, Beley S (2023) Safety and feasibility of percutaneous needle tunneling with platelet-rich plasma injections for Peyronie\u2019s disease in the outpatient setting: a pilot study. Int J Impot Res. https:\/\/doi.org\/10.1038\/s41443-023-00744-y","journal-title":"Int J Impot Res"},{"key":"5065_CR29","doi-asserted-by":"publisher","DOI":"10.15761\/SHI.1000102","author":"R Virag","year":"2017","unstructured":"Virag R, Sussman H, Lambion S, de Fourmestraux V (2017) Evaluation of the benefit of using a combination of autologous platelet rich-plasma and hyaluronic acid for the treatment of Peyronie\u2019s disease. Sexual Health Issues. https:\/\/doi.org\/10.15761\/SHI.1000102","journal-title":"Sexual Health Issues"},{"key":"5065_CR30","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1080\/2090598X.2022.2135284","volume":"21","author":"C Achraf","year":"2023","unstructured":"Achraf C, Abdelghani PA, Jihad PEA (2023) Platelet-rich plasma in patients affected with Peyronie\u2019s disease. Arab J Urol 21:69\u201375. https:\/\/doi.org\/10.1080\/2090598X.2022.2135284","journal-title":"Arab J Urol"},{"key":"5065_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.purol.2023.09.013","author":"M Alshuaibi","year":"2023","unstructured":"Alshuaibi M, Zugail AS, Lombion S, Beley S (2023) New protocol in the treatment of Peyronie\u2019s disease by combining platelet-rich plasma, percutaneous needle tunneling, and penile modeling: preliminary results. Prog Urol. https:\/\/doi.org\/10.1016\/j.purol.2023.09.013","journal-title":"Prog Urol"},{"key":"5065_CR32","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.euf.2022.08.017","volume":"9","author":"KY Chu","year":"2023","unstructured":"Chu KY, Molina ML, Ledesma B, Zucker I, Saltzman RG, Masterson TA et al (2023) A phase 2 randomized, placebo-controlled crossover trial to evaluate safety and efficacy of platelet-rich plasma injections for Peyronie\u2019s disease: clinical trial update. Eur Urol Focus 9:11\u201313. https:\/\/doi.org\/10.1016\/j.euf.2022.08.017","journal-title":"Eur Urol Focus"},{"key":"5065_CR33","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.1423","volume":"3","author":"A Stridh","year":"2020","unstructured":"Stridh A, Pont\u00e9n M, Arver S, Kirsch I, Ab\u00e9 C, Jensen KB (2020) Placebo responses among men with erectile dysfunction enrolled in phosphodiesterase 5 inhibitor trials. JAMA Netw Open 3:e201423. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.1423","journal-title":"JAMA Netw Open"},{"key":"5065_CR34","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.juro.2013.01.087","volume":"190","author":"M Gelbard","year":"2013","unstructured":"Gelbard M, Goldstein I, Hellstrom WJG, McMahon CG, Smith T, Tursi J et al (2013) Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol 190:199\u2013207. https:\/\/doi.org\/10.1016\/j.juro.2013.01.087","journal-title":"J Urol"},{"key":"5065_CR35","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/S0022-5347(06)00270-9","volume":"175","author":"JP Mulhall","year":"2006","unstructured":"Mulhall JP, Schiff J, Guhring P (2006) An analysis of the natural history of Peyronie\u2019s disease. J Urol 175:2115\u20132118. https:\/\/doi.org\/10.1016\/S0022-5347(06)00270-9","journal-title":"J Urol"},{"key":"5065_CR36","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.eururo.2011.07.053","volume":"60","author":"RC Rosen","year":"2011","unstructured":"Rosen RC, Allen KR, Ni X, Araujo AB (2011) Minimal clinically important differences in the erectile function domain of the international index of erectile function scale. Eur Urol 60:1010\u20131016. https:\/\/doi.org\/10.1016\/j.eururo.2011.07.053","journal-title":"Eur Urol"},{"key":"5065_CR37","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1111\/j.1743-6109.2009.01496.x","volume":"6","author":"AC De Araujo","year":"2009","unstructured":"De Araujo AC, Da Silva FG, Salvi F, Awad MC, Da Silva EA, Dami\u00e3o R (2009) The management of erectile dysfunction with placebo only: does it work? J Sex Med 6:3440\u20133448. https:\/\/doi.org\/10.1111\/j.1743-6109.2009.01496.x","journal-title":"J Sex Med"},{"key":"5065_CR38","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0090-4295(98)00643-8","volume":"53","author":"F Montorsi","year":"1999","unstructured":"Montorsi F, McDermott TED, Morgan R, Olsson A, Schultz A, Kirkeby HJ et al (1999) Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies. Urology 53:1011\u20131018. https:\/\/doi.org\/10.1016\/S0090-4295(98)00643-8","journal-title":"Urology"},{"key":"5065_CR39","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/j.jsxm.2022.06.003","volume":"19","author":"K Khodamoradi","year":"2022","unstructured":"Khodamoradi K, Dullea A, Golan R, Molina M, Arora H, Masterson TA et al (2022) Platelet rich plasma (PRP) growth factor concentration varies in men with erectile dysfunction. J Sex Med 19:1488\u20131493. https:\/\/doi.org\/10.1016\/j.jsxm.2022.06.003","journal-title":"J Sex Med"},{"key":"5065_CR40","doi-asserted-by":"publisher","first-page":"189","DOI":"10.4103\/0974-2077.150734","volume":"7","author":"R Dhurat","year":"2014","unstructured":"Dhurat R, Sukesh M (2014) Principles and methods of preparation of platelet-rich plasma: a review and author\u2032s perspective. J Cutan Aesthet Surg 7:189. https:\/\/doi.org\/10.4103\/0974-2077.150734","journal-title":"J Cutan Aesthet Surg"},{"key":"5065_CR41","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/andr.12648","volume":"8","author":"R Bader","year":"2020","unstructured":"Bader R, Ibrahim JN, Moussa M, Mourad A, Azoury J, Azoury J et al (2020) In vitro effect of autologous platelet-rich plasma on H2O2 -induced oxidative stress in human spermatozoa. Andrology 8:191\u2013200. https:\/\/doi.org\/10.1111\/andr.12648","journal-title":"Andrology"},{"key":"5065_CR42","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/aor.14505","volume":"47","author":"M Salem","year":"2023","unstructured":"Salem M, Feizollahi N, Jabari A, Golmohammadi MG, Shirinsokhan A, Ghanami Gashti N et al (2023) Differentiation of human spermatogonial stem cells using a human decellularized testicular scaffold supplemented by platelet-rich plasma. Artif Organs 47:840\u2013853. https:\/\/doi.org\/10.1111\/aor.14505","journal-title":"Artif Organs"},{"key":"5065_CR43","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.cryobiol.2021.01.009","volume":"98","author":"B Yan","year":"2021","unstructured":"Yan B, Zhang Y, Tian S, Hu R, Wu B (2021) Effect of autologous platelet-rich plasma on human sperm quality during cryopreservation. Cryobiology 98:12\u201316. https:\/\/doi.org\/10.1016\/j.cryobiol.2021.01.009","journal-title":"Cryobiology"},{"key":"5065_CR44","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s10561-022-10032-6","volume":"24","author":"MS Nabavinia","year":"2023","unstructured":"Nabavinia MS, Yari A, Ghasemi-Esmailabad S, Gholoobi A, Gholizadeh L, Nabi A et al (2023) Improvement of human sperm properties with platelet-rich plasma as a cryoprotectant supplement. Cell Tissue Bank 24:307\u2013315. https:\/\/doi.org\/10.1007\/s10561-022-10032-6","journal-title":"Cell Tissue Bank"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-05065-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-024-05065-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-05065-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T21:32:23Z","timestamp":1735853543000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-024-05065-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,29]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5065"],"URL":"https:\/\/doi.org\/10.1007\/s00345-024-05065-3","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,29]]},"assertion":[{"value":"18 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mikkel Fode is a speaker for Boston Scientific.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This systematic review does not involve any human participants or animals. Therefore, ethical approval or animal care guidelines were not required for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human or animal participants"}},{"value":"Informed consent is not applicable to this narrative review manuscript as it does not involve human participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"359"}}